Vivani Medical’s chief business officer buys $1,110 in stock

Donald Dwyer, the Chief Business Officer of Vivani Medical (TASE:BLWV), Inc. (NASDAQ:VANI), a small-cap healthcare company with a market capitalization of $64.57 million, recently acquired 1,000 shares of the company’s common stock. The purchase was executed on February 28, 2025, at $1.11 per share, amounting to $1,110. According to InvestingPro, the stock shows high volatility with a beta of 3.5. This transaction was carried out on the open market, increasing Dwyer’s total holdings to 51,000 shares. With the company’s next earnings report due on March 27 and analyst price targets ranging from $3 to $8, investors seeking deeper insights into insider trading patterns and company fundamentals can access additional analysis through InvestingPro, which features 7 more key investment tips for VANI.

In other recent news, Vivani Medical has made significant progress with its LIBERATE-1 clinical trial for the exenatide implant, NPM-115. The trial, which began patient screening and enrollment in Australia, aims to evaluate the safety, tolerability, and pharmacokinetics of the implant in overweight or obese participants. Participants are pre-treated with semaglutide injections before being randomized into three groups for different treatment regimens. The primary focus of the trial is on changes in participants’ weight, with top-line data expected by mid-2025.

Additionally, H.C. Wainwright has reaffirmed a Buy rating on Vivani Medical’s shares, citing confidence in the potential market impact of NPM-115. The firm has set a price target of $3.00, highlighting the convenience of biannual administration compared to current treatments. Vivani’s CEO, Adam Mendelsohn, emphasized the implant’s potential to offer efficacy comparable to semaglutide, a widely used treatment. The company plans to leverage Australian government incentives to offset trial costs and aims to use the data for regulatory submissions in various regions. These developments mark a significant step in Vivani Medical’s efforts to address chronic weight management challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.